Aberrant activation of MYCN, for instance, has been frequently linked to the development of neuroblastoma, retinoblastoma, leukemia, and, more recently, hepatocellular carcinoma (Rickman et al., 2018; Qin et al., 2018). Here, MYCN is linked to retinoblastoma.